Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ascrinvacumab (PF-03446962) in advanced malignant pleural mesothelioma
NCT01486368Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jun 2012
- Primary completion
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ascrinvacumab in malignant pleural mesothelioma (MPM), sponsored by Canadian Cancer Trials Group. Started Jun 2012; status: completed.
02
Drugs
ascrinvacumab
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT01486368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01486368.